COMMENTARY
Transcatheter aortic valve replacement (TAVR) has become a
well-established therapy for patients with severe aortic stenosis,
preferred, in many cases to surgical aortic valve replacement (SAVR).
However, despite advances in technologies and clinical experience,
conduction disorders represent the weak point of this procedure,
requiring permanent pacemaker implantation (PPI) till 37.7% of patients
(1).
In a single-centre retrospective study, Bin Mahmood et al. (2) sought to
discover the impact of PPI on mid-term mortality in SAVR and TAVR
patients. Prevalence of PPI was 7.2% and 18.1% in SAVR and TAVR,
respectively. In this examination there was no correlation between PPI
and mid-term mortality in both SAVR (HR 0.69, CI 0.21-2.30; p=0.56) and
TAVR (HR 0.70, CI 0.42-1.17 p=0.18) patients. Median follow-up duration
was 1.9 years and 2.5 years in the SAVR and TAVR group, respectively.
This study provides reassuring conclusions about outcomes in TAVR and
SAVR patients treated with PPI. One important limitation is the
short-term follow-up that may not be enough to detect a negative effect
of PPI on clinical outcomes.
The role of PPI in TAVR and SAVR remains controversial in mid- and
long-term outcomes. Indeed, many studies have been published with
contradictory results, leaving doubts rather than certainties. The
prevalence of PPI in TAVR patients is high. A recent meta-analysis (3)
showed, in 40,181 patients, a PPI rate of 19.2% in balloon-expandable,
24.7% in self-expandable and 34.8% in mechanically-expandable valves.
In SAVR patients, on the contrary, PPI prevalence is 4%, as found
analysing 5,600 patients undergone SAVR in Netherlands from 2013 to 2019
(4). This explains why any PPI-related problem is more carefully
evaluated in TAVR patients.
Buellesfeld et al. (5) reported a similar outcome in patients with or
without PPI at 12 months follow up, as other Authors (6) (7) did.
Recently Rück et al. (8) after a median follow-up period of 2.7 years
(2.5-11.8) years, found no difference in long-term survival between
patients who did and did not require PPI after TAVR.
On the other hand, J. Lopez-Aguilera et al. (9) found that, after TAVR
with CoreValve, there was a significant difference in overall all-cause
mortality, with a decreased survival of patients in PPI group at 3-3.5
years, while there was no longer a significant difference in survival
curves, at 5-6 years. These results were consistent with a study of
Dizon et al. (10) and were confirmed in a recent meta-analysis (11),
that found, at a follow-up longer than 1 year, a negative impact on
all-cause mortality and heart failure rehospitalization in PPI group in
patients undergone TAVR, without difference in long-term cardiovascular
mortality.
The same contradictions can be found in the SAVR. Greason et al.
observed worse long-term survival among patients who underwent PPI after
SAVR (12), while Bagur et al. (13) came to a different and opposite
conclusion.
It is not easy to understand why results are different and often
contradictory. First of all, we know that permanent right ventricular
pacing can impact negatively on mortality and hospitalization for heart
failure. In the Dual-Chamber and VVI Implantable Defibrillation (DAVID)
trial (14), patients treated with a rate responsive pacing (DDD 70 bpm)
instead of back-up pacing (VVI 40 bpm) had a significant increase in the
composite end point of mortality and hospitalization for heart failure
(HR 1.61; 95% CI 1.06–2.44). This means that the deleterious impact of
PPI on cardiac function is stronger if cumulative time of ventricular
pacing is higher, especially in patients with long-term pacing
percentage ≥ 40%; the impact of PPI on late mortality is then depending
also from the rate of pacing, with a low impact on mortality if time of
pacing is low (15) (16). Moreover, conduction abnormalities in TAVR
might also be transient, as it has been demonstrated that up to 50% of
the TAVR patients who implanted a PPI did not need any pacing with time
(17). We then have patients with PPI who will have the same outcome than
patients without, but still included in PPI group. It is possible that
the outcome of both groups (with and without PPI) could be similar. As a
matter of fact, information on ventricular pacing was not available in
most of the studies.
This means that we cannot translate the results of the DAVID trial into
patients undergoing TAVR. Another question is still unanswered: which is
the the optimal timing for PPI after TAVR? Should it to be postponed
beyond the 7 days currently recommended after SAVR to determine if
rhythm disturbances are temporary or permanent?
Another point to take into consideration is that patients undergone TAVR
are old (18). The potential protective effects of PPI with respect to
lethal bradyarrhythmias may counterbalance the negative effects of
ventricular pacing. Furthermore, after the treatment of aortic stenosis,
improvement of left ventricular function may compensate for the
deleterious effects of right ventricular pacing. Due to advanced age,
most of the studies have a short follow up and reflect the natural
history of aged patients where a single factor (PPI) cannot be such to
cause a difference in a survival that is, anyway, short.
Indeed, studies on SAVR have a longer follow up. In a recent study (19)
that evaluated PPI in SAVR, the mean and maximum follow-up periods were
7.3 years and 22.0 years, respectively, and at 10 years and 20 years
after surgical treatment, all-cause mortality was statistically
significantly increased in the PPI group compared with the non-PPI
group. This conclusion is however questioned by the study by Bin Mahmood
et al (2), who found no difference in survival, but with a shorter
follow up.
To date, the impact of PPI in TAVR or SAVR recipients is still unclear
and management of conduction abnormalities after TAVR is challenging. As
stated by 2021 ESC Guidelines on cardiac pacing (20), the impact of PPI
on late outcomes after TAVR remains controversial. Unnecessary PPI has
to be minimized, especially in an era when transcatheter AVR is used
among younger patients at lower risk.